Accueil   Diary - News   All news Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

 


• This Phase 3 clinical program will enroll over 1,300 people with diabetes and is expected to be pivotal for product registration in China
• First patient in the study will trigger a milestone payment to Adocia
• BC Lispro addresses the Chinese prandial insulin market which is approx. $1.4bn today with double-digit growth

 

 

Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatments and other metabolic diseases with innovative formulations of proteins and peptides, announced today that its partner Tonghua Dongbao Pharmaceutical Co. Ltd. (Shanghai:600867) received clearance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the Phase 3 clinical trial of BioChaperone® Lispro, an Ultra-Rapid Insulin for the treatment of Type 1 and Type 2 diabetes. The first patient enrolled in the program will trigger a milestone payment to Adocia.


“We are delighted to enter into the Phase 3 program for one of the two products licensed to Tonghua Dongbao, the domestic insulin leader in China. ”, commented Gerard Soula, President & CEO of Adocia.

 

 

READ THE PRESS RELEASE